Facebook
Twitter
LinkedIn
Forward
The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects an estimated 25-30% of people in the United States and can often progress to Metabolic dysfunction-associated steatohepatitis (MASH) and cirrhosis. MASH represents a metabolic-driven array of multi-organ pathology that intersects with obesity, prediabetes, type 2 diabetes, and cardiovascular ailments. Many agents are currently in development for treatment of MASH, including glucagon-like peptide-1 receptor agonists (GLP1-Ras). Although not FDA-approved specifically for MASLD, GLP1-RAs is utilized for obesity and type 2 diabetes treatment. It has demonstrated the ability to reverse steatohepatitis, lower cardiovascular risk, and is considered safe for use across various stages of MASLD, regardless of fibrosis presence. This review outlines the role of GLP1-RAs in treating MASLD/MASH.
Target Audience
The educational design of this activity addresses the needs of U.S.-based gastroenterologists, hepatologists, primary care physicians, and allied health care professionals such as nurses, nurse practitioners, and pharmacists.
Learning Objectives
After completing this activity, the participant should be better able to:
- Explain MAFLD/MASH pathogenesis and the role that cardiovascular and cardiometabolic risk factors, including obesity and diabetes, play in MASH progression in order to improve the identification of MASH
- Recognize current and emerging approaches and tools to screen and diagnose MAFLD and MASH in clinical practice
- Summarize the current guidelines and recommendations for treatment of MASH, including recent consensus statements
- Review the rationale, efficacy and safety of GLP-1 RAs for the treatment of MASH
- List other emerging agents that are in clinical development for MASH
Layla A. Abushamat, MD
Section of Cardiovascular Research
Department of Medicine
Baylor College of Medicine
Houston, TX
Pir Ahmad Shah, MD
Gastroenterology and Hepatology
Creighton University
Phoenix, AZ
Robert H. Eckel, MD
Professor of Medicine, Emeritus
University of Colorado Anschutz Medical Campus
Denver, CO
Stephen A. Harrison, MD, FACP, FAASLD
Medical Director, Pinnacle Clinical Research
San Antonio, TX
Diana Barb, MD
Clinical Associate Professor, University of Florida
Gainesville, FL
ESTIMATED TIME TO COMPLETE ACTIVITY
0.75 hours
EDUCATIONAL GRANT SUPPORT
Supported by an educational grant from Novo Nordisk.
JOINT PROVIDERSHIP STATEMENT
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Tarsus Medical Education (TME). PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING EDUCATION
PACE designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NURSING CONTINUING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hours. Pharmacotherapy contact hours for Advance Practice Registered Nurses will be designated on your certificate.
PHARMACY CONTINUING EDUCATION
PACE designates this continuing education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number - JA4008073-9999-24-097-H01-P Type of activity: Knowledge
For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.
METHOD OF PARTICIPATION & REQUEST FOR CREDIT
There are no registration fees for this activity. Participation in this self-study activity should be completed in approximately 0.75 hour(s). To successfully complete this activity and receive CE credit, learners must follow these steps during the period from May 6, 2024 through May 6, 2025.
- Review the objectives and disclosures
- Study the educational content
- Successfully complete activity post-test(s)
- Complete the activity evaluation
You must receive a test score of at least 75% and respond to all evaluation questions to receive a certificate. Upon completing, your certificate will be available for print. For questions about receiving certificates, please contact us at CMHC_Eval@cardiometabolichealth.org. For additional information about the accreditation of this activity, please visit https://partnersed.com
DISCLOSURES
PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.
Dr. Abushamat has nothing to disclose.
Dr. Barb, faculty for this educational activity, discloses the following:
- Coinvestigator for clinical trials in MASH, sponsored by Inventiva, Janssen, Sirius, Novo Nordisk pharmaceuticals, and Novartis Institute.
Dr. Eckel, faculty for this educational activity, discloses the following:
- Consultant: Amgen, Better Company, Ionis, Novo Nordisk, The Healthy Aging Co, and WW International.
Dr. Harrison, faculty for this educational activity, discloses the following:
- Advisory Board/Panels: Akero Therapeutics, Inc, Altimmune, Inc, Arrowhead Pharmaceuticals, Inc, Axcella Health, Inc, Bvf Partners, Chronwell, Inc, Echosens North America, Inc, Foresite Labs, LLC, Galectin Therapeutics, Inc, Genfit Corp, Gilead Sciences, Inc, Hepion Pharmaceuticals, Inc, Hightide Therapeutics, Inc, Histoindex PTE Ltd, Intercept Pharmaceuticals, Inc, Madrigal Pharmaceuticals, Inc, Medpace, Inc, Metacrine, Inc, Ngm Biopharmaceuticals, Inc, Northsea Therapeutics BV, Novartis Pharmaceuticals Corp, Novo Nordisk, Pathai, Inc, Poxel, Sagimet Biosciences, Sonic Incytes Medical Corp, and Terns, Inc.
- Consultant: AgomAB, Akero Therapeutics, Inc, Alentis Therapeutics AG, Alimentiv, Inc, Altimmune, Inc, Axcella Health, Inc, Blade Therapeutics, Bluejay Therapeutics, Boston Pharmaceuticals, Boxer Capital, Canfite Biopharma Ltd, Cirius Therapeutics, Inc, Civi Biopharma, Inc, Cldf, Cohbar, Inc, Corcept, Cymabay Therapeutics, Inc, Echosens North America, Inc, Enyo Pharma SA, Fibronostics, Inc, Foresite Labs, LLC, Fortress Biotech, Inc, Galectin Therapeutics, Inc, Galecto, Inc, Galmed Research & Dev, Ltd, Gelesis, Inc, Genfit Corp, Gilead Sciences, Inc, Glaxo Smith Kline, GNS Healthcare, Inc, GRI Bio, Hepagene Therapeutics, Hepion Pharmaceuticals, Inc, Hepta Bio Inc, Hightide Therapeutics, Inc, Histoindex PTE Ltd, Indalo Therapeutics, Inc, Inipharm, Inc, Innovate Biopharmaceuticals, Inc, Intercept Pharmaceuticals, Inc, Ionis, Kowa Research Institute, Inc, Madrigal Pharmaceuticals, Inc, Medpace, Inc, Merck Sharp & Dohme Corp, Metacrine, Inc, MGGM Therapeutics LLC, Neurobo Pharmaceuticals Inc, Ngm Biopharmaceuticals, Inc, Northsea Therapeutics BV, Novartis Pharmaceuticals Corp, Novo Nordisk, Nutrasource, Perspectum Diagnostics, Inc, Pfizer, Piper Sandler & Co, Poxel, Prometic (Now Liminal), Ridgeline Therapeutics, Sagimet Biosciences, Silverback Therapeutics, Inc, Sonic Incytes Medical Corp, Terns, Inc, Viking Therapeutics, Inc, and Zafgen.
- Received research grants from: Akero Therapeutics, Inc, Axcella Health, Inc, BMS, Cirius Therapeutics, Inc, CiVi Biopharma, Inc, Conatus, Cymabay Therapeutics, Inc, Enyo Pharma SA, Galectin Therapeutics, Inc, Galmed Research & Dev, Ltd, Genentech (Subsidiary of Roche), Genfit Corp, Hepion Pharmaceuticals, Inc, Hightide Therapeutics, Inc, Immuron, Intercept Pharmaceuticals, Inc, Madrigal Pharmaceuticals, Inc, Ngm Biopharmaceuticals, Inc, Northsea Therapeutics BV, Novartis Pharmaceuticals Corp, Novo Nordisk, Pfizer, Poxel, Sagimet Biosciences, Second Genome, Inc, Viking Therapeutics, Inc.
- Stocks/stock options: Akero Therapeutics, Inc, Chronwell, Inc, Cirius Therapeutics, Inc, Galectin Therapeutics, Inc, Genfit Corp, Hepion Pharmaceuticals, Inc, Hepta Bio Inc, Histoindex Pte. Ltd, Metacrine, Inc, Ngm Biopharmaceuticals, Inc, Northsea Therapeutics BV, and Sonic Incytes Medical Corp.
Dr. Shah has nothing to disclose.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Available Credit
- 0.75 ACPE Pharmacy
- 0.75 AMA PRA Category 1 Credit™
- 0.75 ANCC
- 0.75 Participation
Required Hardware/software
A computer with an internet connection
Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.